Heart Blood Flow Imaging and Walking Test in Hypertrophic Cardiomyopathy Patients
Compares heart blood flow scans with walking distance in adults with obstructive hypertrophic cardiomyopathy.
Key facts
- Who runs it
- Medical University of Vienna
- Where
- Vienna, AustriaSee the site
- Trial code
- Registry title
- Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 5 Sept 2025
- Expected to end
- Sept 2027
- Type of study
- Observational
- Treatments tested
- Mavacamten in clinical routine use
- Record updated
- 2 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obstructive hypertrophic cardiomyopathy (HCM) who already take guideline-based medicine and have a planned heart MRI scan with perfusion imaging.
- Age
- Older than 18 years
- Sex
- All sexes can join
- Disease stage
- Obstructive HCM diagnosed by the 2023 ESC criteria
- Earlier treatment
- Must be receiving guideline-conform optimal medical therapy
Main reasons for not taking part
- Claustrophobia or another reason that rules out a heart MRI scan
- Significant coronary artery disease, prior stent or coronary bypass surgery
- Sudden cardiac arrest or sustained ventricular arrhythmia in the 12 months before screening
- Glomerular filtration rate below 30ml/min/m2, or significant liver problems
- Known allergy to contrast agent, or another disease that causes the heart thickening
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age > 18 years
- Willingness to provide written informed consent
- Diagnosis of obstructive HCM based on ESC 2023 criteria
- Planned CMR with myccardial perfusion for clinical purposes
- Receiving guideline-conform OMT
- Ability and willingness to undergo follow-up imaging and testing
- Written informed consent
Who cannot take part
- Significant coronary artery disease and/or prior stent implantation or coronary artery bypass graft surgery
- History of sudden cardiac arrest or sustained ventricular arrhythmia 12 months prior to screening
- Known allergy to contrast agent
- Alternative disease causing hypertrophic cardiomyopathy (e.g. cardiac amyloidosis, Morbus Fabry)
- Significant hepatic impairment defined as 3x upper limit of normal of transaminases, total bilirubin, or alkaline phosphatase; hepatic cirrhosis
- Claustrophobia or other contraindication for CMR imaging
- Glomerular filtration rate < 30ml/min/m2
- Pregnant women (and women with childbearing potential with desire for pregnancy)
- Breastfeeding women
- Unwillingness to comply with the study protocol and its procedures
Where in Austria
- Medical University of ViennaVienna, AustriaContact: Daniel Dalos, PD DDr.Taking people
About the trial
What the trial wants to find out
Background: Microvascular dysfunction is a hallmark of hypertrophic obstructive cardiomyopathy (HOCM) and can be visualized non-invasively using cardiac magnetic resonance (CMR) perfusion imaging. In parallel, the six-minute walk test (6MWT) is an established clinical tool to assess submaximal exercise capacity in patients with structural heart disease. Despite its widespread use, the relationship between objective changes in myocardial perfusion and functional improvements assessed by the 6MWT remains insufficiently explored in patients with HOCM on optimal medical therapy (OMT).
Read full original descriptionShow less
Aim:This study aims to evaluate whether changes in functional capacity, measured by the 6MWT, correlate with changes in myocardial perfusion reserve (MPR) in HOCM patients treated with OMT.
Methods: We will include patients diagnosed with obstructive HCM who previously underwent clinically indicated CMR perfusion scans for risk stratification. These patients are regularly followed in the HCM outpatient clinic of the Medical University of Vienna, where standardized 6MWTs are performed in routine care. Approximately one year after the baseline CMR, a follow-up CMR will be conducted to assess changes in perfusion parameters. This second CMR is clinically justified for improved individual risk stratification as recommended by the 2023 ESC Guidelines on Cardiomyopathies.
The primary objective is to assess the correlation between the change in the walking distance in the 6MWT and the change in MPR over a one-year interval. Secondary endpoints include changes in myocardial blood flow (MBF) at rest and during pharmacological stress. All assessments will be integrated with clinical, echocardiographic, and laboratory evaluations.
Treatments tested
- Mavacamten in clinical routine use
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy
- Plain-language title
- Heart Blood Flow Imaging and Walking Test in Hypertrophic Cardiomyopathy PatientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 September 2025